What Is Transcatheter Aortic Valve Implantation (TAVI)?

Transcatheter aortic valve implantation, commonly called TAVI (or TAVR in North America, for “transcatheter aortic valve replacement”), is a minimally invasive procedure that replaces a diseased aortic valve without open-heart surgery. Instead of opening the chest and stopping the heart, a cardiologist threads a compressed replacement valve through a blood vessel and positions it inside the old, failing valve. The technique was first performed in a human patient in 2002 and has since expanded from a last resort for people too sick for surgery to a mainstream treatment offered even to low-risk patients.

The Problem TAVI Solves

The aortic valve sits between the heart’s main pumping chamber and the aorta, the large artery that delivers blood to the rest of the body. In calcific aortic stenosis, calcium deposits gradually stiffen and thicken the valve’s leaflets, narrowing the opening the heart must push blood through. This is the most common heart-valve disorder in developed countries, and it gets worse over time as the obstruction to blood flow grows more severe.¹ As the valve narrows, the heart muscle thickens to compensate for the extra work. Eventually that compensation fails, leading to symptoms like breathlessness, chest pain, and fainting, along with a sharply rising risk of heart failure and death.²

No drug can reverse severe aortic stenosis once it develops. Before TAVI existed, the only definitive treatment was surgical aortic valve replacement (SAVR), which requires a large chest incision, a heart-lung bypass machine, and weeks of recovery. Many elderly or frail patients were simply told they were too sick for surgery, leaving them with limited options. Balloon valvuloplasty, a procedure that temporarily stretches the narrowed valve open with an inflatable balloon, was tried in the early 1990s, but its results did not last. That frustration motivated the development of a valve that could be delivered by catheter and left permanently in place.³

A Brief History of the Procedure

The idea of implanting a valve through a catheter dates to the early 1990s. Postmortem studies in 1993 showed that a stent-mounted valve could be placed inside a calcified aortic valve, and animal testing followed in 2000. French cardiologist Alain Cribier performed the first human implantation in Rouen, France, in 2002.⁴ Early devices were bulky, leakage around the new valve was common, and because only the sickest patients were treated, mortality was high. Surgical colleagues and device manufacturers were initially skeptical, which slowed progress.³ By 2005, improved devices and broader clinical trials began to demonstrate that TAVI could match surgical outcomes. The European Conformity (CE) mark was granted in 2007 for two types of valves, and large registries showed steadily improving results as technology and operator experience grew.⁴ Today, hundreds of thousands of procedures are performed worldwide each year.

How the Procedure Works

The most common approach is transfemoral, meaning the valve is delivered through the femoral artery in the groin. A puncture is made, a guidewire is threaded up through the aorta, and the replacement valve, compressed onto a delivery catheter, is guided into position inside the diseased native valve. Once in place, the new valve is expanded, either by inflating a balloon (balloon-expandable valves) or by releasing a self-expanding frame that springs open on its own. The old valve leaflets are pushed aside, and the new valve immediately takes over.

Accurate sizing before the procedure is essential. CT scanning of the aortic root lets the team measure the valve opening precisely and choose the right device size, reducing the chance of leakage or other complications.⁵ CT-derived measurements tend to be slightly larger than those from ultrasound (echocardiography) because CT captures the oval, asymmetric shape of the valve opening more faithfully, which matters when selecting a valve that needs to seal tightly against calcified tissue.⁶

When the femoral artery is too narrow, heavily calcified, or otherwise unsuitable, alternative access points are used. The subclavian artery, just below the collarbone, is one option. A meta-analysis found that short-term mortality and complication rates were broadly similar between the subclavian and femoral routes, although the subclavian approach took longer and the femoral approach carried a higher rate of major blood vessel injuries.⁷ Other routes exist as well, including through the chest wall directly into the heart’s apex, though these are less commonly needed with today’s slimmer catheter systems.

Balloon-Expandable vs. Self-Expanding Valves

Two main valve designs dominate the field. Balloon-expandable valves are crimped onto a balloon catheter and deployed by inflating the balloon at the target site. Self-expanding valves are held in a compressed state by a sheath and spring open when the sheath is retracted. Each design has trade-offs. Self-expanding valves tend to produce slightly lower pressure gradients across the valve after implantation, meaning blood flows through them a little more easily. Balloon-expandable valves, on the other hand, tend to have lower rates of leakage around the valve and a lower chance of needing a permanent pacemaker afterward.⁸ Data from the large French TAVI registry found that self-expanding valves were associated with somewhat higher rates of paravalvular regurgitation and higher mortality at two years compared with balloon-expandable valves.⁹ Newer-generation devices of both types continue to narrow these differences.

Who Gets TAVI

Initially, TAVI was reserved for patients who could not survive open-heart surgery at all. In a landmark trial of such inoperable patients, those who received TAVI had a three-year mortality rate of about 54%, compared to roughly 81% for those managed with medication alone.¹⁰ That dramatic survival advantage established the procedure’s value and opened the door to trials in higher-functioning patients.

Subsequent studies moved TAVI into intermediate-risk and then low-risk surgical populations. Two pivotal low-risk trials changed the landscape. The PARTNER 3 trial found that among 1,000 low-risk patients, the combined rate of death, stroke, or rehospitalization at one year was about 8.5% with TAVI versus 15.1% with surgery. The Evolut Low Risk trial, using a different valve platform, showed the rate of death or disabling stroke at two years was 5.3% with TAVI versus 6.7% with surgery, confirming that TAVI was at least as good as surgery in this population.¹¹ Longer follow-up of the PARTNER 3 patients at five years showed the primary combined endpoint remained similar between the two groups, with a trend favoring TAVI that was driven mainly by fewer rehospitalizations.¹²

Decisions about who receives TAVI versus surgery are made by a “heart team” of cardiologists, cardiac surgeons, and imaging specialists. Risk scores, age, frailty, anatomy, and patient preference all factor in. In practice, older patients and those with preserved heart-pumping function are more likely to be steered toward TAVI, while younger patients or those with anatomy that complicates catheter delivery may still be better served by surgery.¹³

How TAVI Compares to Surgery Overall

A systematic review and meta-analysis pooling data from randomized trials across all risk categories found that death from any cause was similar between TAVI and surgery at every time point examined, from 30 days out to five years. Stroke rates were also similar. Where the two approaches differed was in their complication profiles. TAVI was associated with less major bleeding, less acute kidney injury, and lower rates of new-onset atrial fibrillation. On the other side, TAVI patients were more likely to need a permanent pacemaker, had more vascular complications at the catheter insertion site, and experienced more leakage around the new valve. Hospital stays were roughly three days shorter with TAVI.¹⁴ A separate meta-analysis echoed these findings, noting that while early and mid-term mortality favored TAVI or was equivalent, there was a trend toward slightly higher long-term mortality with TAVI at the two-to-five-year mark that did not reach statistical significance, particularly among lower-risk patients where data were still limited.¹⁵

Complications and How They Are Managed

TAVI is minimally invasive, but it is not complication-free. Several risks are specific to the catheter-based approach.

Conduction Disturbances and Pacemakers

The heart’s electrical wiring runs very close to the aortic valve. When a new valve frame is expanded into position, it can bruise or compress the conduction fibers, causing heart-rhythm problems. The most common disturbances are high-grade heart block and new left bundle branch block. Some of these resolve on their own within days, but others require a permanent pacemaker. The rate of pacemaker implantation varies depending on the type of valve used, the depth of implantation, and whether the patient already had conduction abnormalities before the procedure.¹⁶ Pre-existing right bundle branch block, in particular, has been linked to a higher chance of needing a pacemaker after TAVI.¹⁷

Paravalvular Leak

Because TAVI places a new valve inside the old, calcified one rather than sewing a replacement into surgically prepared tissue, small gaps can remain between the valve frame and the surrounding anatomy. Blood seeping through these gaps is called paravalvular leak. Even mild leakage matters: a meta-analysis of individual patient data found that any degree of paravalvular leak after TAVI was associated with a roughly 50% higher risk of death over follow-up, along with increased rehospitalization and cardiovascular mortality.¹⁸ Advances in valve design, better CT-guided sizing, and post-dilation techniques have all reduced leak rates over successive device generations.

Vascular Complications

Threading a large catheter through an artery can injure the blood vessel, especially if the vessel is small or heavily calcified. Iliofemoral complications are the most frequent vascular issue in transfemoral TAVI. Vessel diameter and the degree of calcification are the main predictors, along with operator experience. Treatment options when an access-site injury occurs include balloon angioplasty, stent placement, or surgical repair.¹⁹ The ratio of the catheter sheath diameter to the artery diameter is a strong predictor of trouble; when that ratio gets close to or exceeds 0.9, the risk of vascular injury climbs substantially regardless of the puncture technique used.²⁰

Stroke and Cerebral Protection Devices

Stroke is one of the most feared complications, and it has driven interest in cerebral embolic protection devices, small filters placed in the arteries leading to the brain to catch debris dislodged during the procedure. A large systematic review and meta-analysis found that patients receiving these devices had a 30% lower risk of stroke and a 56% lower risk of disabling stroke compared with unprotected TAVI.²¹ However, this picture is muddied by conflicting evidence. Two separate analyses that included trial sequential analysis, a method for assessing whether enough patients have been studied to draw firm conclusions, found no significant reduction in stroke or mortality with protection devices and determined that the current body of evidence is not yet large enough to confirm a clinical benefit.²²²³ The debate over routine use of these filters remains active.

Quality of Life After TAVI

For patients whose daily lives have been dominated by breathlessness and fatigue, the functional improvement after TAVI can be striking. In a prospective study of elderly Italian patients, quality-of-life scores across every measured domain, including physical functioning, pain, vitality, and mental health, improved sharply within five months and remained at those improved levels through one year. Before the procedure, patients scored far below what would be expected for their age group in the general population. Afterward, their scores essentially matched it.²⁴

Even among patients in their eighties, the gains are meaningful. In a study of octogenarians, survival at about 16 months was over 85%, nearly half could walk unassisted, and roughly four out of five reported improved self-awareness and well-being. Most described their quality of life as “good” or “acceptable for their age.” Patients aged 85 and older still benefited, though the proportion reporting “good” quality of life was somewhat lower.²⁵ A recent study specifically looking at patients aged 90 and older found rapid quality-of-life gains at 30 days, with heart-failure-specific scores improving by a median of 39 points and visual-analogue quality-of-life scores improving by 25 points. These gains were largely sustained at 12 months, though frailty and the presence of multiple other illnesses influenced how much benefit individual patients experienced.²⁶

How Long Do TAVI Valves Last

Durability has been one of the biggest unanswered questions, because the oldest TAVI valves have only had about 10 to 15 years of follow-up. A clinical review concluded that the risk of structural valve deterioration may actually be lower after TAVI than after surgical valve replacement over a five-to-ten-year window, and that the two approaches carry a similar risk of complete valve failure.²⁷ A large European registry with a median follow-up of about six years found that moderate or severe structural valve deterioration occurred in roughly one in ten patients. The strongest predictors of deterioration were the use of an intra-annular (rather than supra-annular) valve design, a small valve size, and moderate or severe paravalvular leak after the initial procedure.²⁸

This matters especially for younger patients. A 75-year-old who receives a TAVI valve may need it to function for 15 or 20 years, and the long-term data beyond a decade are still thin. The theoretical advantage of TAVI for younger, lower-risk patients must be weighed against the possibility that valve-in-valve procedures, where a second transcatheter valve is placed inside a deteriorating first one, could be needed down the road. This is an active area of research, and it is one of the main reasons heart teams still sometimes recommend surgery in younger patients whose anatomy is favorable for an open approach.

Blood Thinners After the Procedure

After any new valve is implanted, there is a risk of blood clots forming on the device. Finding the right balance between preventing clots and avoiding excessive bleeding has been a moving target. Randomized trials found that single antiplatelet therapy, meaning one blood-thinning medication like aspirin alone, produces less bleeding than dual antiplatelet therapy (aspirin plus a second agent) with no increased risk of clot-related events. For patients who already need lifelong anticoagulation for another condition like atrial fibrillation, adding an antiplatelet drug on top of the anticoagulant increases bleeding without improving outcomes. Current guidelines recommend single antiplatelet therapy for patients without another reason for anticoagulation, and anticoagulant alone for those who do have such a reason.²⁹

TAVI for Bicuspid Aortic Valves

Most aortic valves have three leaflets, but roughly 1 to 2% of the population is born with a bicuspid valve, meaning only two leaflets. Bicuspid valves are prone to calcifying and narrowing earlier in life and have a different shape than three-leaflet valves, which poses challenges for a procedure designed around typical anatomy. Elliptical openings, asymmetric calcium deposits, and larger aortic roots can all complicate valve sizing and deployment.³⁰

With current-generation devices, outcomes have improved considerably. A report from the STS/ACC national registry found that procedural results and one-year outcomes were comparable between bicuspid and standard three-leaflet valve patients when newer devices were used.³¹ A systematic review and meta-analysis confirmed similar device success and one-year survival rates, but noted that patients with bicuspid valves had higher rates of moderate-to-severe paravalvular leak and a slightly elevated risk of brain-related events and annular rupture compared with standard anatomy patients.³² TAVI is feasible in selected bicuspid patients, but the anatomy demands careful planning and patient selection.

Cost-Effectiveness

TAVI devices are expensive, often costing substantially more than surgical valves. Whether the higher device price is offset by shorter hospital stays and faster recovery depends on the healthcare system and time horizon considered. A Swedish economic analysis of low-risk patients found that TAVI produced a small gain in quality-adjusted survival at a modestly higher cost, resulting in a cost-effectiveness ratio well within what Sweden considers acceptable for healthcare spending.³³ A UK analysis reached a similar conclusion, estimating that TAVI added about half a quality-adjusted life-year per patient over a lifetime, with a cost-effectiveness ratio that fell comfortably under the National Health Service’s willingness-to-pay threshold.³⁴ In lower-income healthcare systems, access remains limited because the upfront device cost can be prohibitive even if the overall value equation makes sense over time.

Could Drugs Replace Valve Replacement Someday

There is currently no approved medication that can halt or reverse calcific aortic stenosis once it has set in.³⁵ That has not stopped researchers from looking. Recent and ongoing trials are testing a range of approaches aimed at either slowing calcium buildup or reducing the inflammatory and metabolic processes that drive it. Among the candidates being studied are lipid-lowering therapies, drugs targeting the nitric oxide pathway, vitamin K supplementation, medications from the diabetes toolkit being repurposed for their anti-inflammatory properties, colchicine (an old anti-inflammatory drug), and drugs that stabilize a protein called transthyretin.³⁶ None of these has yet proven effective enough to change practice, and even optimistic researchers acknowledge that pharmacotherapy is more likely to slow progression in early disease than to replace valve intervention once stenosis becomes severe. For the foreseeable future, procedures like TAVI and surgical replacement remain the only options once the valve has narrowed enough to cause symptoms.